Breakdown of neuro-glial N-acetyl-aspartate (NAA) metabolism results in the failure of developmental myelination, manifest in the congenital pediatric leukodystrophy Canavan disease caused by mutations to the sole NAA catabolizing enzyme aspartoacylase. Canavan disease is a major point of focus for efforts to define NAA function, with available evidence suggesting NAA serves as an acetyl donor for fatty acid synthesis during myelination. Elevated NAA is a diagnostic hallmark of Canavan disease, which contrasts with a broad spectrum of alternative neurodegenerative contexts in which levels of NAA are inversely proportional to pathological progression. Recently generated data in the nur7 mouse model of Canavan disease suggests loss of aspartoacylase function results in compromised energetic integrity prior to oligodendrocyte death, abnormalities in myelin content, spongiform degeneration, and motor deficit. The present study utilized a next-generation "oligotropic" adeno-associated virus vector (AAV-Olig001) to quantitatively assess the impact of aspartoacylase reconstitution on developmental myelination. AAV-Olig001-aspartoacylase promoted normalization of NAA, increased bioavailable acetyl-CoA, and restored energetic balance within a window of postnatal development preceding gross histopathology and deteriorating motor function. Long-term effects included increased oligodendrocyte numbers, a global increase in myelination, reversal of vacuolation, and rescue of motor function. Effects on brain energy observed following AAV-Olig001-aspartoacylase gene therapy are shown to be consistent with a metabolic profile observed in mild cases of Canavan disease, implicating NAA in the maintenance of energetic integrity during myelination via oligodendroglial aspartoacylase.
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Introduction
Canavan disease is an autosomal recessive leukodystrophy caused by deficiency in aspartoacylase (ASPA) (Hagenfeldt et al., 1987) , an oligodendroglial enzyme (Baslow et al., 1999) (Francis et al., 2006) . Based on these diverse roles, it follows that the effects of dysregulated NAA in Canavan disease are likely multi-factorial. Given the genetic defect underlying Canavan disease is manifest primarily in the oligodendroglial compartment, targeting of this specific lineage is required to address the relative prominence of these multifactorial effects and provide insight into pathogenic mechanisms of relevance to clinical endpoints.
NAA rises linearly with age in Canavan disease (Janson et al., 2006b; Leone et al., 2012) alongside progressive spongiform encephalopathy and diffuse white matter loss. Mitochondrial dysfunction has long been suspected based on ultrastructural studies (Gambetti et al., 1969) , and a relatively unexplored role for NAA in uncoupling the Neurobiology of Disease 96 (2016) 323-334 
